Alloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology Ecosystem

April 2, 2021 | Alloy Therapeutics

Funds to be used to advance platforms and resources used by scientific entrepreneurs to turn ideas into biological medicines.

Read More: Press Release | Business Wire | Business Insider | Fierce Biotech | Scrip | Wall Street Journal Pro | EndPoints News | Boston Business Journal  | Bio Century

Stanford and Alloy Therapeutics Collaborate to Develop Antibody Prototypes for Innovative Medicines Accelerator

March 3, 2021 | Stanford Innovative Medicines Accelerator

Stanford has obtained a worldwide, non-exclusive license to use the immunocompetent Alloy-Gx transgenic mice for in vivo human antibody discovery for research, development, and commercialization. 

Read More…

Evotec Partners with Alloy Therapeutics to Expand its Antibody Discovery Platform

December 21, 2020 | Evotec

Evotec SE and Alloy Therapeutics, a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, today announced that the companies have entered into a technology partnership to expand Evotec’s antibody discovery platform.

Read More…

Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases

December 7, 2020 | Maze Therapeutics

Maze Therapeutics and Alloy Therapeutics announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases. 

Read More: Press Release | Fierce Biotech | Endpoints | SF Business Times

Alloy Therapeutics Becomes BaseLaunch’s First Dedicated Antibody Discovery Domain Partner

November 24, 2020 | BaseLaunch

Alloy Therapeutics joins BaseLaunch’s endeavor to fuel the next generation of exceptional biotechnology companies. 

Read More…

AbCellera Announces Agreement with Alloy Therapeutics to Integrate Access to ATX-Gx™ Humanized Mice Platform for Antibody Discovery Programs

July 21, 2020 | AbCellera

AbCellera announced that it has entered into an agreement with Alloy Therapeutics to use the ATX-Gx™ humanized mice platform to enable best-in-class in vivo human antibody discovery for its partner programs. 

Read More…

US Antibody Ace Leverages Cambridge Base

June 10, 2020 | Business Weekly

Alloy Therapeutics, formed in Massachusetts in 2017, is dedicated to empowering global scientists with foundational drug discovery platforms and services. It is hiring fresh talent at its new UK home at Granta’s McLintock Building. 

Read More…